Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

No Definitive Link Found Between Physical Activity and Prostate Cancer

March 1, 2018
By Dave Levitan
Article

A meta-analysis was unable to find a conclusive relationship between physical activity and the risk of prostate cancer, though a reduced risk was suggested.

A large meta-analysis was unable to find a conclusive relationship between levels of physical activity and the risk of prostate cancer, though some suggestion of reduced risk was seen for occupational activity and for some specific cancer subtypes. There was also indication that physical activity after diagnosis of prostate cancer might have a protective effect.

“Knowledge about risk factors of prostate cancer is limited, complicating the formulation of appropriate strategies for the prevention of prostate cancer,” wrote study authors led by Daniela Schmid, MSc, of the University of Regensburg in Germany. “The role of potential modifiable risk factors for the development of prostate cancer such as obesity, smoking, poor diet, and physical activity is less well understood.”

The authors conducted a meta-analysis and review of studies of physical activity and prostate cancer, including 48 cohort studies and 24 case-control studies incorporating a total of 151,748 cases of prostate cancer. The mean age of the study participants at baseline was 61 years. Results were published in Annals of Oncology.

The primary analysis relating physical activity to prostate cancer revealed an association that was close to null, with a relative risk (RR) of 0.99 (95% CI, 0.94–1.04) comparing the highest and lowest categories of activity. The same held true when the case-control and the cohort studies were examined separately.

They then stratified by the domain of physical activity, and found a significant inverse association between long-term occupational activity and total prostate cancer incidence, with an RR of 0.83 (95% CI, 0.71–0.98) and a borderline association with short-term occupational physical activity with an RR of 0.85 (95% CI, 0.72–1.00). However, the long-term significant RR did not remain significant after removal of individual studies from the analysis.

When stratifying by both type of physical activity and subtypes of prostate cancer, further associations were seen. There was an inverse association between long-term recreational physical activity and advanced/aggressive prostate cancer, with an RR of 0.75 (95% CI, 0.60–0.95), though this incorporated only 2 studies. There was also an inverse association between long-term occupational physical activity and non-advanced/non-aggressive prostate cancer, with an RR of 0.51 (95% CI, 0.37–0.71), again with 2 studies.

There was no association seen between pre-diagnosis physical activity and mortality due to prostate cancer. However, there was an inverse association between physical activity after diagnosis and prostate cancer mortality among survivors, with an RR of 0.69 (95% CI, 0.55–0.85), based on 4 studies.

“These associations may represent an indication for a potential protective effect of long-term activity on prostate cancer incidence,” the authors wrote. “However, our findings must be interpreted with caution.” The analysis’s sensitivity to removal of individual studies, and the small number of studies that revealed some of the significant results, make interpretation difficult. “Despite a growing body of literature on physical activity and prostate cancer incidence, evidence for a link between overall physical activity and risk of prostate cancer remains elusive.”

Recent Videos
Considering which non–muscle-invasive bladder cancer cases may be cured by surgery alone may help mitigate overtreatment in this patient group.
Event-free survival benefit was observed among BCG-naïve patients with carcinoma in situ undergoing treatment with sasanlimab plus BCG.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
Related Content
Advertisement

Changes in FKSI-15 scores from baseline indicated more favorable HRQOL outcomes with the benmelstobart combo vs sunitinib in advanced ccRCC.

Benmelstobart Combo Elicits PFS Advantage in Untreated Advanced ccRCC

Roman Fabbricatore
September 5th 2025
Article

Changes in FKSI-15 scores from baseline indicated more favorable HRQOL outcomes with the benmelstobart combo vs sunitinib in advanced ccRCC.


Beyond the BEP: A Deep Dive into Testicular Cancer Management

Beyond the BEP: A Deep Dive into Testicular Cancer Management

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Nabil Adra, MD
August 28th 2025
Podcast

Discover key takeaways on tumor markers, the BEP vs. EP debate, and the role of surgery in stage II testicular cancer.


FDA OKs Leuprolide Mesylate 3-Month Formulation in Advanced Prostate Cancer

FDA OKs Leuprolide Mesylate 3-Month Formulation in Advanced Prostate Cancer

Ariana Pelosci;Tim Cortese
August 29th 2025
Article

Results from a phase 3 trial led to the approval of leuprolide mesylate as a 3-month formulation for patients with advanced prostate cancer.


Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD
June 5th 2025
Podcast

Experts weigh in on the practical applications of PSMA PET imaging


Developers are enrolling those with metastatic castration-resistant prostate cancer on a phase 1/2 trial to assess the safety and tolerability of HLD-0915.

HLD-0915 Earns FDA Fast Track Designation in Metastatic CRPC

Roman Fabbricatore
August 14th 2025
Article

Developers are enrolling those with metastatic castration-resistant prostate cancer on a phase 1/2 trial to assess the safety and tolerability of HLD-0915.


Adverse reactions in the phase 3 ENVISION trial were largely mild to moderate in severity, and serious reactions occurred in 12% of those with NMIBC.

Mitomycin Exhibits Durable Responses in Recurrent, Low-Grade NMIBC

Roman Fabbricatore
August 7th 2025
Article

Adverse reactions in the phase 3 ENVISION trial were largely mild to moderate in severity, and serious reactions occurred in 12% of those with NMIBC.

Related Content
Advertisement

Changes in FKSI-15 scores from baseline indicated more favorable HRQOL outcomes with the benmelstobart combo vs sunitinib in advanced ccRCC.

Benmelstobart Combo Elicits PFS Advantage in Untreated Advanced ccRCC

Roman Fabbricatore
September 5th 2025
Article

Changes in FKSI-15 scores from baseline indicated more favorable HRQOL outcomes with the benmelstobart combo vs sunitinib in advanced ccRCC.


Beyond the BEP: A Deep Dive into Testicular Cancer Management

Beyond the BEP: A Deep Dive into Testicular Cancer Management

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Nabil Adra, MD
August 28th 2025
Podcast

Discover key takeaways on tumor markers, the BEP vs. EP debate, and the role of surgery in stage II testicular cancer.


FDA OKs Leuprolide Mesylate 3-Month Formulation in Advanced Prostate Cancer

FDA OKs Leuprolide Mesylate 3-Month Formulation in Advanced Prostate Cancer

Ariana Pelosci;Tim Cortese
August 29th 2025
Article

Results from a phase 3 trial led to the approval of leuprolide mesylate as a 3-month formulation for patients with advanced prostate cancer.


Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD
June 5th 2025
Podcast

Experts weigh in on the practical applications of PSMA PET imaging


Developers are enrolling those with metastatic castration-resistant prostate cancer on a phase 1/2 trial to assess the safety and tolerability of HLD-0915.

HLD-0915 Earns FDA Fast Track Designation in Metastatic CRPC

Roman Fabbricatore
August 14th 2025
Article

Developers are enrolling those with metastatic castration-resistant prostate cancer on a phase 1/2 trial to assess the safety and tolerability of HLD-0915.


Adverse reactions in the phase 3 ENVISION trial were largely mild to moderate in severity, and serious reactions occurred in 12% of those with NMIBC.

Mitomycin Exhibits Durable Responses in Recurrent, Low-Grade NMIBC

Roman Fabbricatore
August 7th 2025
Article

Adverse reactions in the phase 3 ENVISION trial were largely mild to moderate in severity, and serious reactions occurred in 12% of those with NMIBC.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.